Cdsco

Is Centre giving ‘expired’ COVID-19 vaccines to teenagers? A look at the shelf life of a jab and what the row is about

The Centre on Monday issued a clarification, calling reports of expired Covaxin doses being administered to children aged 15-18 ‘misleading and false’

Bharat Biotech submits vaccine data for phase 2/3 trials on children between 2-18 years to DCGI

The paediatric Covaxin is similar to the one administered to adults - two doses of the vaccine given 28 days apart.

Bharat Biotech’s intranasal vaccine for COVID-19: Everything we know so far about BBV154

The intranasal vaccine BBV154 is being tested to check if it prevents infection, halts person-to-person transmission, and progression of COVID-19.

Moderna's COVID-19 vaccine gets approval for restricted emergency use, confirms Centre

Earlier news agency PTI had reported that the DCGI has granted permission to Cipla to import Moderna's COVID-19 vaccine for restricted emergency use in the country.

Centre discontinues Remdesivir allocation to states, says supply much more than demand

Mandaviya said the production of Remdesivir has been increased ten times from just around 33,000 vials per day on 11 April to around 3,50,000 vials per day as of today

Eli Lilly inks pacts for COVID-19 drug Baricitinib with Torrent Pharma, Dr Reddy's and MSN Labs

The drug Baricitinib will be used in combination with Remdesivir for the treatment of patients requiring supplemental oxygen, invasive mechanical ventilation, Eli Lilly and Company said in a statement

SEC recommends Bharat Biotech’s Covaxin phase 2, 3 clinical trials on 2- to 18-year-olds

The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS Patna and Meditrina Institute of Medical Sciences, Nagpur.

Over 160 L COVID-19 vaccine doses procured so far, but beneficiaries below target due to hesitancy, govt tells LS

Giving out the details of the number of vaccines already procured by the government, Minister of State for Health Ashwini Choubey said the total cost of procurement of above mentioned doses of vaccines is Rs 350.25 crore

SEC recommends Bharat Biotech's COVAXIN for emergency use as India tests its vaccine delivery system

The recommendation for Bharat Biotech's vaccine came a day after the COVID-19 expert panel cleared the Serum Institute of India's emergency use authorisation application for the Oxford-AstraZeneca vaccine 'Covishield'

Coronavirus News Updates: COVID-19 expert panel recommends emergency use authorisation for Bharat Biotech's COVAXIN

Coronavirus News LIVE Updates: Covaxin has been indigenously developed by Bharat Biotech in collaboration with the ICMR